Fol. Biol. 2024, 70, 189-195
https://doi.org/10.14712/fb2024070040189
Predictive Value of T-Lymphocyte Subsets in Combination with Serum Tumour Markers for Prognosis of Patients with Non-Small Cell Lung Cancer Undergoing Chemotherapy
References
1. , T. (2018) Staging of non-small-cell lung cancer. PET Clin. 13, 1-10.
<https://doi.org/10.1016/j.cpet.2017.09.004>
2. , J. N., Boumber, Y., Borghaei, H. (2020) Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer 126, 260-270.
<https://doi.org/10.1002/cncr.32468>
3. , S. W., Zhu, S. Q., Pei, X. et al. (2021) Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC. Mol. Cancer 20, 144.
<https://doi.org/10.1186/s12943-021-01448-x>
4. , N., Santana-Davila, R., Molina, J. R. (2019) Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin. Proc. 94, 1623-1640.
<https://doi.org/10.1016/j.mayocp.2019.01.013>
5. , D. S., Wood, D. E., Aisner, D. L. (2017) Non-small cell lung cancer, Version 5. 2017, NCCN Clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 15, 504-535.
<https://doi.org/10.6004/jnccn.2017.0050>
6. , S. S., Paliogiannis, P., Zinellu, A. et al. (2021) Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer. Int. J. Mol. Sci. 22, 612.
<https://doi.org/10.3390/ijms22020612>
7. , F., Korol, E. E., Kayaniyil, S. et al. (2019) Efficacy and safety of first-line carboplatin versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 135, 196-204.
<https://doi.org/10.1016/j.lungcan.2019.07.010>
8. , H., Nogami, N., Saka, H. et al. (2021) Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan study. Cancer Sci. 112, 3255-3265.
<https://doi.org/10.1111/cas.14980>
9. , B. L., Morgan, D. M., Momin, N. et al. (2021) Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Sci. Immunol. 6, eabi8800.
<https://doi.org/10.1126/sciimmunol.abi8800>
10. , D., Shen, W., Gong, C. et al. (2021) Grain-sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non-small cell lung cancer. J. Cell. Mol. Med. 25, 2900-2908.
<https://doi.org/10.1111/jcmm.16320>
11. , C., Deneer, V. H. M., Kelder, J. C. et al. (2020) Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Thorac. Cancer 11, 1790-1800.
<https://doi.org/10.1111/1759-7714.13449>
12. , H., Jamiyan, T., Yamaguchi, R., et al. (2021) Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast. BMC Cancer 21, 286.
<https://doi.org/10.1186/s12885-021-08009-x>
13. , Z., Wang, T., She, Y. et al. (2021) N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol. Cancer 20, 105.
<https://doi.org/10.1186/s12943-021-01398-4>
14. , A., Chai, E., Berglund, K. et al. (2021) Using admission Karnofsky performance status as a guide for palliative care discharge needs. J. Palliat. Med. 24, 910-913.
<https://doi.org/10.1089/jpm.2020.0543>
15. , A., Singh, N., Shyam, H. et al. (2021) Differential expression profiling of transcripts of IDH1, CEA, Cyfra21-1, and TPA in stage IIIa non-small cell lung cancer (NSCLC) of smokers and non-smokers cases with air quality index. Gene 766, 145151.
<https://doi.org/10.1016/j.gene.2020.145151>
16. , J., Mei, Q., Chen, L. et al. (2021) Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives. Cancer Immunol. Immunother. 70, 619-631.
<https://doi.org/10.1007/s00262-020-02735-0>
17. , E., Leithner, K., Olschewski, H. (2020) Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: clinical significance and limitations. Thorac. Cancer 11, 205-215.
<https://doi.org/10.1111/1759-7714.13246>
18. , S., Lee, J. S., Kang, J. H. et al. (2021) Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann. Oncol. 32, 1137-1147.
<https://doi.org/10.1016/j.annonc.2021.06.004>
19. , J., Chen, X., Wang, Y. (2020) Comparison of the diagnostic value of CEA combined with OPN or DKK1 in non-small cell lung cancer. Oncol. Lett. 20, 3046-3052.
<https://doi.org/10.3892/ol.2020.11846>
20. , L., Luo, Y., Tian, J. et al. (2022) A validated nomogram integrating baseline peripheral T-lymphocyte subsets and NK cells for predicting survival in stage I-IIIA non-small cell lung cancer after resection. Ann. Transl. Med. 10, 250.
<https://doi.org/10.21037/atm-21-6347>
21. , S., Yokoyama, Y., Sonohara, F. et al. (2020) Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preoperative therapy. J. Hepatobiliary Pancreat. Sci. 27, 487-495.
<https://doi.org/10.1002/jhbp.748>
22. , Y., Wang, X., Liu, C. et al. (2022) Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study. BMC Pulm. Med. 22, 166.
<https://doi.org/10.1186/s12890-022-01951-x>
23. , Q., Zhang, L., Tu, M. et al. (2021) Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma. Clin. Chim. Acta 520, 126-132.
<https://doi.org/10.1016/j.cca.2021.06.013>
